FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089735243> ?p ?o ?g. }

• W3089735243 endingPage "565" @default.
• W3089735243 startingPage "558" @default.
• W3089735243 abstract "Leber hereditary optic neuropathy (LHON) leads to bilateral central vision loss. In a clinical trial setting, idebenone has been shown to be safe and to provide a trend toward improved visual acuity, but long-term evidence of effectiveness in real-world clinical practice is sparse.Open-label, multicenter, retrospective, noncontrolled analysis of long-term visual acuity and safety in 111 LHON patients treated with idebenone (900 mg/day) in an expanded access program. Eligible patients had a confirmed mitochondrial DNA mutation and had experienced the onset of symptoms (most recent eye) within 1 year before enrollment. Data on visual acuity and adverse events were collected as per normal clinical practice. Efficacy was assessed as the proportion of patients with either a clinically relevant recovery (CRR) or a clinically relevant stabilization (CRS) of visual acuity. In the case of CRR, time to and magnitude of recovery over the course of time were also assessed.At time of analysis, 87 patients had provided longitudinal efficacy data. Average treatment duration was 25.6 months. CRR was observed in 46.0% of patients. Analysis of treatment effect by duration showed that the proportion of patients with recovery and the magnitude of recovery increased with treatment duration. Average gain in best-corrected visual acuity for responders was 0.72 logarithm of the minimal angle of resolution (logMAR), equivalent to more than 7 lines on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Furthermore, 50% of patients who had a visual acuity below 1.0 logMAR in at least one eye at initiation of treatment successfully maintained their vision below this threshold by last observation. Idebenone was well tolerated, with most adverse events classified as minor.These data demonstrate the benefit of idebenone treatment in recovering lost vision and maintaining good residual vision in a real-world setting. Together, these findings indicate that idebenone treatment should be initiated early and be maintained more than 24 months to maximize efficacy. Safety results were consistent with the known safety profile of idebenone." @default.
• W3089735243 created "2020-10-08" @default.
• W3089735243 creator A5001718634 @default.
• W3089735243 creator A5003057063 @default.
• W3089735243 creator A5003631947 @default.
• W3089735243 creator A5009133924 @default.
• W3089735243 creator A5011270152 @default.
• W3089735243 creator A5011286807 @default.
• W3089735243 creator A5012156268 @default.
• W3089735243 creator A5015209790 @default.
• W3089735243 creator A5023642805 @default.
• W3089735243 creator A5026565602 @default.
• W3089735243 creator A5028870246 @default.
• W3089735243 creator A5029667259 @default.
• W3089735243 creator A5030880288 @default.
• W3089735243 creator A5033873486 @default.
• W3089735243 creator A5037328246 @default.
• W3089735243 creator A5037805514 @default.
• W3089735243 creator A5040452344 @default.
• W3089735243 creator A5041342462 @default.
• W3089735243 creator A5042741456 @default.
• W3089735243 creator A5045531332 @default.
• W3089735243 creator A5047515036 @default.
• W3089735243 creator A5048844265 @default.
• W3089735243 creator A5053530903 @default.
• W3089735243 creator A5055916230 @default.
• W3089735243 creator A5056029326 @default.
• W3089735243 creator A5061016538 @default.
• W3089735243 creator A5062060255 @default.
• W3089735243 creator A5062426098 @default.
• W3089735243 creator A5065117631 @default.
• W3089735243 creator A5065120691 @default.
• W3089735243 creator A5066037096 @default.
• W3089735243 creator A5069653369 @default.
• W3089735243 creator A5070419882 @default.
• W3089735243 creator A5075183333 @default.
• W3089735243 creator A5079328144 @default.
• W3089735243 creator A5085967575 @default.
• W3089735243 date "2020-09-22" @default.
• W3089735243 modified "2023-10-18" @default.
• W3089735243 title "Real-World Clinical Experience With Idebenone in the Treatment of Leber Hereditary Optic Neuropathy" @default.
• W3089735243 cites W1519380020 @default.
• W3089735243 cites W1971317397 @default.
• W3089735243 cites W1975584416 @default.
• W3089735243 cites W1977023305 @default.
• W3089735243 cites W1995208181 @default.
• W3089735243 cites W1998025788 @default.
• W3089735243 cites W2004334615 @default.
• W3089735243 cites W2040661873 @default.
• W3089735243 cites W2070864958 @default.
• W3089735243 cites W2105795226 @default.
• W3089735243 cites W2108045023 @default.
• W3089735243 cites W2108286632 @default.
• W3089735243 cites W2112785879 @default.
• W3089735243 cites W2124154990 @default.
• W3089735243 cites W2133321491 @default.
• W3089735243 cites W2138558536 @default.
• W3089735243 cites W2144080933 @default.
• W3089735243 cites W2152856466 @default.
• W3089735243 cites W2168124117 @default.
• W3089735243 cites W2169456218 @default.
• W3089735243 cites W2392032054 @default.
• W3089735243 cites W2763147200 @default.
• W3089735243 cites W4242520386 @default.
• W3089735243 cites W4376095966 @default.
• W3089735243 cites W99108903 @default.
• W3089735243 doi "https://doi.org/10.1097/wno.0000000000001023" @default.
• W3089735243 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7657145" @default.
• W3089735243 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32991388" @default.
• W3089735243 hasPublicationYear "2020" @default.
• W3089735243 type Work @default.
• W3089735243 sameAs 3089735243 @default.
• W3089735243 citedByCount "60" @default.
• W3089735243 countsByYear W30897352432020 @default.
• W3089735243 countsByYear W30897352432021 @default.
• W3089735243 countsByYear W30897352432022 @default.
• W3089735243 countsByYear W30897352432023 @default.
• W3089735243 crossrefType "journal-article" @default.
• W3089735243 hasAuthorship W3089735243A5001718634 @default.
• W3089735243 hasAuthorship W3089735243A5003057063 @default.
• W3089735243 hasAuthorship W3089735243A5003631947 @default.
• W3089735243 hasAuthorship W3089735243A5009133924 @default.
• W3089735243 hasAuthorship W3089735243A5011270152 @default.
• W3089735243 hasAuthorship W3089735243A5011286807 @default.
• W3089735243 hasAuthorship W3089735243A5012156268 @default.
• W3089735243 hasAuthorship W3089735243A5015209790 @default.
• W3089735243 hasAuthorship W3089735243A5023642805 @default.
• W3089735243 hasAuthorship W3089735243A5026565602 @default.
• W3089735243 hasAuthorship W3089735243A5028870246 @default.
• W3089735243 hasAuthorship W3089735243A5029667259 @default.
• W3089735243 hasAuthorship W3089735243A5030880288 @default.
• W3089735243 hasAuthorship W3089735243A5033873486 @default.
• W3089735243 hasAuthorship W3089735243A5037328246 @default.
• W3089735243 hasAuthorship W3089735243A5037805514 @default.
• W3089735243 hasAuthorship W3089735243A5040452344 @default.
• W3089735243 hasAuthorship W3089735243A5041342462 @default.
• W3089735243 hasAuthorship W3089735243A5042741456 @default.
• W3089735243 hasAuthorship W3089735243A5045531332 @default.

• next